ENTRY       D11516                      Drug
NAME        Faricimab (USAN/INN);
            Faricimab (genetical recombination) (JAN);
            Faricimab-svoa;
            Vabysmo (TN)
PRODUCT     VABYSMO (Genentech)
FORMULA     C6506H9968N1724O1026S45
EXACT_MASS  130108.8251
MOL_WEIGHT  130194.6203
SEQUENCE    (A chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW INPNSGGTNY
            AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSP NPYYYDSSGY YYPGAFDIWG
            QGTMVTVSSA SVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN
            SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGECDKTH
            TCPPCPAPEA AGGPSVFLFP PKPKDTLMAS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV
            HNAKTKPREE QYNSTYRVVS VLTVLAQDWL NGKEYKCKVS NKALGAPIEK TISKAKGQPR
            EPQVCTLPPS RDELTKNQVS LSCAVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF
            FLVSKLTVDK SRWQQGNVFS CSVMHEALHN AYTQKSLSLS PGK
            (B chain)
            EVQLVESGGG LVQPGGSLRL SCAASGYDFT HYGMNWVRQA PGKGLEWVGW INTYTGEPTY
            AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP YYYGTSHWYF DVWGQGTLVT
            VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
            QSSGLYSLSS VVTVPSSSLG TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEA
            AGGPSVFLFP PKPKDTLMAS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE
            QYNSTYRVVS VLTVLAQDWL NGKEYKCKVS NKALGAPIEK TISKAKGQPR EPQVYTLPPC
            RDELTKNQVS LWCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK
            SRWQQGNVFS CSVMHEALHN AYTQKSLSLS PGK
            (C chain)
            DIQLTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF TSSLHSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (D chain)
            SYVLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG QAPVLVVYDD SDRPSGIPER
            FSGSNSGNTA TLTISRVEAG DEADYYCQVW DSSSDHWVFG GGTKLTVLSS ASTKGPSVFP
            LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT
            VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSC
            (Disulfide bridge: A22-A96, A156-A216, A236-D213, A242-B232, A245-B235, A277-A337, A365-A441, B22-B96, B150-B206, B226-C214, B267-B327, B360-B431, B23-B88, B134-B194, D22-D87, D137-D193)
  TYPE      Peptide
REMARK      Therapeutic category: 1319
            ATC code: S01LA09
            Product: D11516<JP/US>
EFFICACY    Angiogenesis inhibitor, Anti-angiopoietin 2 antibody, Anti-VEGF antibody
  DISEASE   Neovascular (wet) age-related macular degeneration [DS:H00821]
            Diabetic macular edema [DS:H01651]
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Opthamology indications in patients susceptible to blocking of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2)
TARGET      ANGPT2 [HSA:285] [KO:K05466]
            VEGFA [HSA:7422] [KO:K05448]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01L OCULAR VASCULAR DISORDER AGENTS
                S01LA Antineovascularisation agents
                 S01LA09 Faricimab
                  D11516  Faricimab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Vascular Endothelial Growth Factor (VEGF) Inhibitor
                Faricimab
                 D11516  Faricimab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              13  Agents affecting sensory organs
               131  Ophthalmic agents
                1319  Others
                 D11516  Faricimab (USAN/INN); Faricimab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                VEGFA
                 D11516  Faricimab (USAN/INN) &lt;JP/US&gt;
                ANGPT2
                 D11516  Faricimab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11516
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11516
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11516
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11516
DBLINKS     CAS: 1607793-29-2
            PubChem: 384585492
///
